Activity Summary:
Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.

Activity Summary:
Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this podcast episode, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.

Activity Summary:
This activity will use a case-based format that incorporates the patient voice to discuss patient treatment concerns, translatability of recent study results to clinical practice, and management strategies to improve patient outcomes.

As our understanding of HIV and HIV therapy progress, so do our management approaches. Learning about concerns/barriers that patients with HIV face can lead to improved individualized outcomes as well as place the healthcare professional at the forefront of HIV care.

Activity Summary:
Clinicians often encounter patients having complex clinical scenarios when managing PH where diverse and dynamic diagnostic and therapeutic issues interact. In this webcast archive, Dr. De Marco and Dr. Oudiz discuss complex clinical case scenarios to improve knowledge of the diagnosis and management of hypertension and its application in practice.

Activity Summary:
In the realm of psoriasis management, significant unmet needs persist, primarily due to the challenges associated with treatment adherence, variability in patient response, and the psychosocial impact of the disease. Despite advancements in therapy, healthcare professionals often struggle to balance efficacy, safety, and patient satisfaction. The emerging landscape of targeted therapies, particularly biologics and small molecule agents, offers new hope by providing more effective and tailored treatment options. However, the integration of personalized treatment strategies, and patient-centered care remains crucial for optimizing outcomes and enhancing the quality of life for psoriasis patients. This podcast will discuss these key issues and explore the potential of innovative therapies in improving patient outcomes.

Activity Summary:
Recent data suggests that PAH is now frequently diagnosed in older patients who often present with cardiovascular (CV) comorbidities. Many patients present with CV comorbidities that are uncontrolled, creating a management dilemma for the treating physician. This slide set presents two case studies discussing the clinical approach as well as how to control comorbidities and their impact on the pulmonary circulation with the best treatment approach for this population.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know’ videos from data presented during the 25th International AIDS Conference.

Activity Summary:
Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In this podcast series, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.

Activity Summary:
Hereditary Angioedema (HAE) poses significant challenges for patients and healthcare providers alike, with recurrent attacks impacting quality of life and posing risks of severe complications. While advancements in treatment options have improved acute management, there remains unmet needs in the realm of long-term prophylaxis. In these mini modules, Dr. Timothy Craig and Dr. Marc Riedl will delve into the complexities of HAE management, focusing specifically on emerging solutions for long-term prophylaxis. Through their discussions, they provide insights into the challenges faced by patients with HAE, the limitations of current prophylactic options, and the potential avenues for innovation and improvement in the long-term management of HAE.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of ‘what you need to know’ videos from data presented during the 25th International AIDS Conference.

Activity Summary:
In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
In these mini-modules, expert faculty inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. By using clinical case scenarios, this activity clarifies clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Dr. Orlowski, Dr. Raje, and Dr. Voorhees lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles, resulting in right heart failure and death within 2-3 years of diagnosis if untreated. Despite advances in the diagnosis and treatment of PAH over the last two decades, the prognosis is still poor. Early recognition of disease, institution of effective PAH disease-specific therapy optimized for disease severity, and comprehensive care in specialized centers hold the promise of improving the outcome of patients. PAH is often misdiagnosed or unrecognized in clinical practice and delaying treatment options can worsen outcomes and survival. Diagnostic tests are needed to be done on anyone with unexplained dyspnea and suspected PAH. This slide kit is designed for primary care providers and other non-specialists, using case-based, interactive discussion on tools to improve diagnosis of PAH and the importance of early referral.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
PH is currently divided into World Health Organization (WHO) groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This slide set presents the latest research in diagnosing and managing Group 2-5 in patients, including a discussion of the distinctions in specific groups – CTEPH, PH-ILD, PH-COPD.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Clinical Viewpoints MF includes a curriculum that highlights the very latest clinical data in myelofibrosis. Slides are developed and updated throughout the year by leading MF expert physicians. All content is reviewed and approved by the Clinical Viewpoints MF Planning Committee.

Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenias, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. Patients with MF also have a propensity toward leukemic transformation. Allogeneic hematopoietic stem cell transplantation (aHCT) is the only curative therapy for patients with MF; however, transplant-related morbidity and mortality precludes this option for the majority of patients. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutic targets with drug candidates in late-stage (phase II or III) clinical development for the treatment of MF. This case-based slide kit discusses the pathophysiology, burden diagnosis, current and future treatment strategies, risk stratification, adverse events associated with therapies as well as the importance of patient-centered care.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Clinical Viewpoints PH-ILD includes a curriculum that highlights the very latest clinical data in pulmonary hypertension due to interstitial lung disease (PH-ILD). Slides are developed and updated throughout the year by leading pulmonology expert physicians. All content is reviewed and approved by the Clinical Viewpoints PH-ILD Planning Committee.

The incidence of PH is known to increase among patients with ILD over the course of disease, however, there is a significant overlap of symptoms between fibrotic lung disease and PH. This is known to result in delayed detection and diagnosis. Clinicians need education on the signs and symptoms and how to screen for and detect PH early among patients with ILD. Although right heart catheterization is required to confirm the diagnosis of PH-ILD, other non-invasive and invasive approaches are useful in enabling an early and accurate diagnosis. Additionally, while there have been new insights into assessing and predicting the severity of PH among patients with ILD, mild PH among patients with ILD has been associated with poor outcomes. Identifying patients that have mild PH is therefore pivotal to improving outcomes with treatment. The development and approval of inhaled treprostinil has been an important milestone in PH-ILD. Indeed, new evidence and updates from ongoing clinical trials continue to be presented and published for the treatment of PH-ILD. To improve confidence among practitioners regarding the use of inhaled treprostinil, it is critical that they are abreast with the latest evidence and expert insights. In this on-demand video presentation Dr. Aaron Waxman will walk through examples of using and optimizing inhaled treprostinil therapy in clinical cases.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. Healthcare providers can improve treatment decisions and patient quality of life by staying updated on these developments. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the European Hematology Association (EHA) 2024 Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This clinical clip will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. Healthcare providers can improve treatment decisions and patient quality of life by staying updated on these developments. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the European Hematology Association (EHA) 2024 Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These clinical clips and podcasts are accredited, on-demand presentations that feature experts discussing recent clinical updates, hot topics and treatment options that were presented at EHA June 13-16, 2024. These activities are designed to keep healthcare professionals abreast of the most recent clinical findings.

This series of conference highlights will cover newly diagnosed multiple myeloma, pediatric idiopathic thrombocytopenia purpura (ITP), and myelofibrosis. Please click the links to participate in each of these activities. At the conclusion of the video and/or podcast, please return to that page to complete your evaluation and receive CME/CE credit.

Activity Summary:

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. The Lecture Library offers various topics that can be accessed for AMA, ANCC or ACPE credit. Select your topic of interest and complete the pre/posttest and evaluation.

Continue to visit the Lecture Library series throughout 2024 to view updates from new publications and conference updates. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Activity Summary:
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this series of Clinical Clips, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.

Activity Summary:
Precision therapy has revolutionized the treatment of lung cancer and has made personalized treatment a reality. To this end, the therapeutic landscape for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations has been evolving rapidly. Indeed, ongoing studies are investigating novel agents and combinations that will play a role in earlier and subsequent treatment settings of EGFR mutated NSCLC and are also exploring the utility of additional biomarkers in guiding therapy in EGFR mutated advanced NSCLC. Considering a continual influx of such progress from ongoing trials, clinicians and healthcare professionals will need guidance from key opinion leaders in sifting through recent evidence and identifying practice-changing updates.

This podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.

Activity Summary:
Precision therapy has revolutionized the treatment of lung cancer and has made personalized treatment a reality. To this end, the therapeutic landscape for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations has been evolving rapidly. Indeed, ongoing studies are investigating novel agents and combinations that will play a role in earlier and subsequent treatment settings of EGFR mutated NSCLC and are also exploring the utility of additional biomarkers in guiding therapy in EGFR mutated advanced NSCLC. Considering a continual influx of such progress from ongoing trials, clinicians and healthcare professionals will need guidance from key opinion leaders in sifting through recent evidence and identifying practice-changing updates.

This clinical clip ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.

Activity Summary:
In this podcast series, Drs. Andrew Armstrong and Tanya Dorff will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.

Activity Summary:
The most recent guidelines recommend germline and/or somatic homologous recombination repair (HRR) gene panel testing to identify patients with metastatic prostate cancer that can benefit from poly-ADP ribose polymerase (PARP) inhibitors. However, HRR gene mutation (HRRm) testing rates are low and as a result, many patients with metastatic prostate cancer are unable to avail of these new therapies that have the potential to improve survival outcomes. This has been attributed to limited awareness about testing, inadequate sample, challenges with reimbursement, lack of patient counseling, and costs. Improving clinician and allied healthcare professional familiarity with HRRm testing guidelines and implementation recommendations, is therefore of utmost importance.

In these Mini Modules, Drs. Andrew Armstrong and Tanya Dorff use a discussion and case-based format to clarify the rationale for HRRm testing in metastatic prostate cancer and ensure better integration of the latest guidelines for testing by addressing barriers. The overall aim is to enable appropriate utilization of HRRm testing to ultimately improve outcomes among patients.